Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
ImmuPharma PLC
IMMImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD. Its pre-clinical products include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations for serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection treatment. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom. Address: 1 Bartholomew Close, London, United Kingdom, EC1A 7BL
Analytics
Zielpreis von Wall Street
387.07 GBXKGV
–Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen IMM
Dividenden-Analyse IMM
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
-93 %Verlauf der Dividende IMM
Bewertung der Aktie IMM
Finanzen IMM
Ergebnisse | 2019 | Dynamik |